- Home
- JTAI vs ACXP Comparison
JTAI vs ACXP Comparison
Compare JTAI & ACXP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | JTAI | ACXP |
|---|---|---|
| Founded | 2018 | 2017 |
| Country | United States | United States |
| Employees | 8 | N/A |
| Industry | Blank Checks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.6M | 3.8M |
| IPO Year | N/A | 2021 |
Fundamental Metrics
Financial Performance| Metric | JTAI | ACXP |
|---|---|---|
| Price | $0.10 | $3.96 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 3 |
| Target Price | $0.40 | ★ $143.67 |
| AVG Volume (30 Days) | ★ 16.9M | 5.4M |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.09 | $0.29 |
| 52 Week High | $6.35 | $8.34 |
Technical Indicators
Market Signals| Indicator | JTAI | ACXP |
|---|---|---|
| Relative Strength Index (RSI) | 29.41 | 62.45 |
| Support Level | $0.09 | $3.68 |
| Resistance Level | $0.13 | $5.50 |
| Average True Range (ATR) | 0.01 | 0.50 |
| MACD | 0.02 | 0.40 |
| Stochastic Oscillator | 36.57 | 52.96 |
Price Performance
Historical ComparisonAbout JTAI Jet.AI Inc.
Jet AI Inc is principally involved in the sale of jet cards, which enable holders to use certain aircraft owned, leased by, arranged, and/or managed by Jet Token and others at agreed-upon rates, as well as the sale of fractional interests in aircraft; and the operation of a proprietary booking platform, which functions as a prospecting and quoting platform to arrange private jet travel with third party carriers as well as through Jet Token's leased and managed aircraft.
About ACXP Acurx Pharmaceuticals Inc.
Acurx Pharmaceuticals Inc is a clinical stage biopharmaceutical company developing a new class of antibiotics for infections caused by bacteria listed as priority pathogens by the World Health Organization, Centers for Disease Control and Prevention and Food and Drug Administration. The company's approach is to develop antibiotic candidates with a Gram-positive selective spectrum. The Company's segment consists of the development of clinical and preclinical product candidates for the development of the Company's proprietary new therapies.